+

WO2019165369A2 - Amélioration de thérapies d'augmentation enzymatique par modification de la glycosylation - Google Patents

Amélioration de thérapies d'augmentation enzymatique par modification de la glycosylation Download PDF

Info

Publication number
WO2019165369A2
WO2019165369A2 PCT/US2019/019420 US2019019420W WO2019165369A2 WO 2019165369 A2 WO2019165369 A2 WO 2019165369A2 US 2019019420 W US2019019420 W US 2019019420W WO 2019165369 A2 WO2019165369 A2 WO 2019165369A2
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
modified
glycosylation pattern
native
composition
Prior art date
Application number
PCT/US2019/019420
Other languages
English (en)
Other versions
WO2019165369A3 (fr
Inventor
Kelsey Moody
Aaron WOLFE
Adam BLANDEN
Kris GROHN
Kathleen Kelly
Jennifer DEROSA
Original Assignee
Ichor Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichor Therapeutics, Inc. filed Critical Ichor Therapeutics, Inc.
Publication of WO2019165369A2 publication Critical patent/WO2019165369A2/fr
Publication of WO2019165369A3 publication Critical patent/WO2019165369A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01013—Manganese peroxidase (1.11.1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the disclosed processes, methods, and systems are directed to modified enzymes, compositions thereof, and methods of making and using same.
  • the disclosed modified enzymes are useful in, and as, therapeutic treatments of various disorders and indications.
  • the disorders and indications may involve
  • the disclosed modified enzymes are administered to a patient suffering from a disease of indication related to lysosomal storage.
  • the disclosed modifications may include“editing” of one or more glycans or saccharides on a protein. Editing may involve adding and/or subtracting glycosylation sites (e.g. amino acid changes) in the protein’s amino acid sequence, and/or by post-translational editing (e.g. adding, subtracting saccharides) of the protein, for example through use of transferases, endoglycosidases, and/or exoglycosidases.
  • modified proteins having a glycosylation pattern that differs from that of a native protein (as used herein a native protein has an amino acid sequence that is unmodified and/or a glycosylation pattern that is produced by a eukaryote expressing that protein), wherein the modified protein may be an enzyme with a catalytic activity, at a pH between 4 and 8, that is different than a catalytic activity of the native enzyme. Also disclosed are methods of altering the catalytic activity of an enzyme at a pH between 4 and 8, the method comprising: altering the glycosylation pattern of the enzyme to create a modified enzyme.
  • Also disclosed are methods of treating patient suffering from a disease or condition associated with altered lysosomal storage comprising; modifying a glycosylation pattern of an enzyme to create a modified enzyme; administering the modified enzyme to a patient suffering from the disease or disorder; allowing the modified enzyme to accumulate in the cytoplasm or a cytoplasmic organelle (in one embodiment the lysosome); allowing the modified enzyme to degrade one or more compounds, thereby treating the patient.
  • the glycosylation pattern of the modified enzyme may be modified by: changing one or more amino acid residues within the amino acid sequence of the native enzyme;
  • the modified enzyme is a peroxidase, for example a manganese peroxidase, such as a manganese peroxidase from a fungus that may be Pleurotus ostreatus.
  • FIG. 1 is a graph showing relative specific activity versus pH for three types of one embodiment of a disclosed enzyme that has been: freshly thawed, PNGasF treated, and PNGaseF mock-treated.
  • FIG. 2 is a bar graph showing relative specific activity of embodiment of the disclosed enzyme treated with and without PNGaseF wherein the substrate is A2E.
  • FIG. 3 is a bar graph showing relative specific activity of enzyme treated with and without PNGaseF, and BSA, wherein the substrate is 2,6-dimethoxyphenol (DMP).
  • DMP 2,6-dimethoxyphenol
  • FIG. 4 is a photograph of a coomassie-stained protein gel showing relative molecular masses of untreated native enzyme, native enzyme treated with PNGaseF, denatured enzyme treated with PNGase F, and PNGase F alone. Left lane shows molecular mass standards.
  • FIG. 5 shows ENDO H digestion pattern schematic (upper left), coomassie blue stained SDS PAGE study of rMnP digestion (upper right), and rMnP +/- digestion activity on DMP substrate.
  • FIG. 6 shows B14 digestion pattern schematic (upper left), coomassie blue stained SDS PAGE study of rMnP digestion (upper right), and rMnP +/- digestion activity on DMP substrate.
  • FIG. 7 shows A(1-2,3,6) digestion pattern schematic (upper left), coomassie blue stained SDS PAGE study of rMnP digestion (upper right), and rMnP +/- digestion activity on DMP substrate.
  • FIG. 8 shows A(1-6) digestion pattern schematic (upper left), coomassie blue stained SDS PAGE study of rMnP digestion (upper right), and rMnP +/- digestion activity on DMP substrate.
  • FIG. 9 graph of activity of rMnP +/- A(1-2,3,6) digestion over 4.5 to 7.8 pH.
  • FIG. 10 point graphs of Absorbance vs. Time for non-modified rMnP (top)
  • FIG. 11 graph of triplicate assays for activity of rMnP +/- A(1 -2,3,6) digestion over 4.5 to 7.8 pH; top graph is activity and bottom graph is normalized reaction velocity.
  • FIG. 12 graph of activity of rMnP +/- A(1-6) digestion over 4.5 to 7.8 pH; top graph is activity and bottom graph is normalized reaction velocity.
  • FIG. 13 bar graphs of normalized reaction velocity for rMnP, rMnP treated with A(1-2,3,6), and A(1-6) at pH 5.1 (top), pH 7.2 (middle), and pH 7.5 (bottom).
  • FIG. 14 graph comparing normalized reaction velocity pH profiles for rMnP (blue line), rMnP treated with A(1-2,3,6) (red line), and A(1-6) (grey line).
  • FIG. 15 graph of activity of rMnP +/- ENDO H digestion over 4.5 to 7.8 pH; top graph is activity and bottom graph is normalized reaction velocity.
  • FIG. 16 graph of second activity assay for rMnP +/- ENDO H digestion over 4.5 to 7.8 pH; top graph is activity and bottom graph is normalized reaction velocity.
  • FIG. 17 graph of activity of rMnP +/- A(1-2) digestion over 4.5 to 7.8 pH; top graph is activity and bottom graph is normalized reaction velocity.
  • the disease or condition is related to aggregation or accumulation of materials within a tissue compartment or cellular organelle.
  • the diseases, conditions, and indications may be associated with accumulation of one or more products (for example an aggregate) in an organelle or tissue compartment.
  • the organelle or compartment is characterized by a pH that is not physiologic - that is, the pH is less than about 7 and greater than about 7.5.
  • the disclosed compounds and compositions may be useful in the treatment of aggregate accumulation in lysosomes.
  • the aggregate is lipofuscin, for example lipofuscin build-up in the lysosome of cells in the eye.
  • lipofuscin comprises the bis-retinoid A2E (N-retinylidene-N- retinylethanolamine).
  • the disclosed compound is a modified enzyme having a catalytic activity optimized for lysosomal pH, which is typically less than about pH 6.
  • the glycosylation pattern of an enzyme may aid in determining the catalytic activity of the enzyme at a given pH.
  • altering the glycosylation pattern of an enzyme may raise or lower the enzyme’s activity at a specific pH.
  • the disclosed enzymes are designed to optimize their activity at a pH found in the lysosome.
  • the glycosylation pattern of the enzyme may be altered by changing one or more amino acids in the sequence of the enzyme.
  • glycans are attached to a protein at specific amino acids (e.g. asparagine, arginine, serine, etc.).
  • amino acid changes e.g. a conservative change such as asparagine to glutamine
  • the glycosylation pattern may be altered with glycosidases, and/or glycotransferases. In some embodiments, altering the amino acids in the sequence of the enzyme.
  • glycosylation pattern may include adding or removing carbohydrates from an amino acid, and/or trimming, reshaping, or altering the oligosaccharide at one or more amino acids of the enzyme.
  • the glycosylation pattern of the disclosed enzymes may be modified by removing glycans (one or more saccharides attached to an amino acid side chain), by adding glycans, and/or changing the identity of one or more glycans attached to the enzyme.
  • the total number of glycosylation sites can be modified and/or the identity of one or more of the glycans attached at those sites may be altered.
  • N-linked glycans may be of three forms: mannose, hybrid, and complex oligosaccharides.
  • modifying the glycosylation pattern may include altering the form of the glycan at a specific residue, for example changing a mannose to a complex oligosaccharide.
  • N-linked glycans use of one or more N-glycosidase may be used to remove one or more N-linked glycans from the enzyme.
  • one or more glycosyltransferases may be used to add glycans or saccharides to the enzyme.
  • the amino acid sequence of the enzyme may be altered to alter the pattern of glycosylation.
  • the glycosylation state of the enzyme manganese manganese
  • modifying the glycosylation of manganese peroxidase may modify the pH profile of manganese peroxidase, for example modification of the glycosylation pattern of manganese peroxidase may alter the enzyme’s activity at a given pH.
  • modification may result in an enzyme activity that is higher at pH below 6.0 than above 6.0, while the unmodified enzyme may have maximum activity around 7.0.
  • the disclosed modifications may help aid in degradation of the retinoid A2E in organelles or tissue compartments with a pH that is lower than physiologic pH, for example the lysosomes of retinal pigmented epithelial (RPE) cells, where build-up of A2E is associated with age-related macular degeneration (AMD) and Stargardt’s macular degeneration (SMD).
  • RPE retinal pigmented epithelial
  • A2E age-related macular degeneration
  • SMD Stargardt’s macular degeneration
  • the present methods, compounds, and systems may be useful in the treatment of other diseases or disorders associated with lysosomal storage diseases, as well as other conditions.
  • Glycosylation refers to the process of adding sugar molecules to a protein and/or the pattern of sugar molecules attached to a protein.
  • Sugars, or saccharides may be added to various amino acid side chains, for example: asparagine (‘Asn’ or‘N’), arginine (‘Arg,’ or “R), serine (‘Ser’ or‘S’), threonine (Thr’ or T), tyrosine (Tyr’ or ⁇ ’), hydroxy-lysine (‘Hyl’ is a modified derivative of lysine‘Lys’ or‘K’), hydroxy-proline ( ⁇ rG is a modified derivative of proline‘Pro’ or‘P’), tryptophan (‘Trp’ or ) and combinations thereof.
  • Asparagine ‘Asn’ or‘N’
  • arginine ‘Arg,’ or “R)
  • Ser serine
  • Thr threonine
  • T tyrosine
  • hydroxy-lysine ‘H
  • the glycosylation is /V-linked (attached via a side-chain nitrogen) or O-linked (attached to a side-chain oxygen), but other types of glycosylation are known to those of skill in the art, and may be used in modifying the disclosed proteins and enzymes (e.g. C-linked, carbon, and phopho-linked).
  • Eukaryotes possess various pathways for glycosylating proteins. Other organisms, including Archea, are also able to glycosylate proteins. In most cases, bacteria do not possess the necessary enzymes or pathways for glycosylating proteins, but can, in some cases, be modified to glycosylate proteins. In some cases the glycosylation patterns of a protein may be the same among various organisms.
  • the Asn may be accessible on the surface of the protein, and may be found in the target sequence, for example N-X-S-N- X-T/C (SEQ ID NO:2), or Asn-X (any amino acid)-Ser (serine), Asn-X-Thr (threonine), or Asn-X-Cys (cysteine).
  • SEQ ID NO:2 N-X-S-N- X-T/C
  • Asn-X any amino acid
  • Ser serine
  • Asn-X-Thr threonine
  • Asn-X-Cys cysteine
  • /V-linked glycosylation results from attaching the oligosaccharide to a side chain nitrogen atom of Asn or Arg side-chains.
  • O-linked glycosylation involves attaching an oligosaccharide to the hydroxyl oxygen of Ser, Thr, Tyr, hydroxy-Lys, hydroxy-Pro.
  • C-linked glycosylation involves attaching an oligosaccharide to a carbon on a tryptophan side-chain.
  • the present disclosure is directed to methods that modify the glycosylation pattern of a protein, for example an enzyme.
  • the modification may include changes to the amino acid sequence of the protein and/or changes in the identity or amount of saccharides attached to the protein.
  • the amino acid that accepts the glycan may remain, but amino acids surrounding that residue may be changed to remove a glycosylation site.
  • glycosylation sites may be added by introducing an amino acid change that creates a new glycosylation site.
  • Glycosyltransferases are enzymes that aid in attaching saccharides (sugars or carbohydrates) to nitrogen, oxygen, or carbon atoms. In many embodiments,
  • glycosyltransferases may be useful in building polymeric saccharides (for example linear and branched oligosaccharides and polysaccharides), that is linking two or more saccharide molecules, or they may be used to transfer one or more saccharides to a protein (e.g. an enzyme).
  • polymeric saccharides for example linear and branched oligosaccharides and polysaccharides
  • a protein e.g. an enzyme
  • glycosyltransferases may be used to add saccharides to amino acid side chains and/or add saccharides to saccharides that have been previously added to an amino acid side chain.
  • Various glycosyltransferases are known in the art.
  • glycosyltransferases may modify a proteins activity at a given pH.
  • the protein’s activity may be higher at one pH relative to a second pH.
  • the protein’s activity at one pH may modified to be higher or lower than that of a protein that has not been treated with a glycosyltransferase.
  • Glycosidases may be used to modify the glycosylation pattern of a protein by removing one or more oligosaccharides.
  • glycosidase treatment may result in altering the proteins activity at one or more pH levels. In some embodiments, this may be used to modify an enzyme’s pH profile. For example, an enzyme’s activity at a given pH may be increased or decreased, relative to that enzyme not treated with a glycosidase.
  • glycosidase treatment may help to modify a disclosed enzyme’s activity to be high in a low pH environment, for example the lysosome, and lower in an environment with physiologic pH.
  • Various glycosidases are known in the art. Exoglycosidase hydrolyzes the glycosidic bond at the terminal sugar residue, while nndoglycosidases cleave
  • a(1 ,2)-Mannosidase specifically cleaves a(1-2)-linked mannose from the non-reducing terminus of glycans; a(1-2,3,6)-Mannosidase releases non-reducing terminal a(1-2,3,6)- linked mannose from oligosaccharides; b-Mannosidase hydrolyzes terminal, non-reducing b- D-mannose residues in b-D-mannosides; Endoglycosidase H hydrolyzes N-linked oligosaccharides; and a1-6 Mannosidase removes unbranched a1-6 linked mannose residues from oligosaccharides.
  • Peptide N-Glycosidase F, commonly referred to as PNGase F.
  • PNGase F is an enzyme that catalyzes hydrolysis of amids into a carboxylic acid and NH 3 .
  • PNGase F belongs to a class of enzymes referred to as peptide-N4-(N-acetyl-beta- glucosaminyl) asparagine amidases.
  • PNGase F cleaves the glycan between the innermost GlcNAc and asparagine residues of high mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins and glycopeptides.
  • One of skill in the art may use the disclosed or other glycosidases, alone or in combination, to practice the disclosed method of modifying a protein.
  • Most enzymes have optimal catalytic activity at or about physiological pH, which in most cases is about 7.2-7.5.
  • physiological pH which in most cases is about 7.2-7.5.
  • the pH of blood is normally about 7.3-7.5, and is normally maintained between about pH 7.35 and 7.45.
  • the intracellular, cytosolic pH of most cells is about 7.2.
  • other compartments and fluids may have a pH that is other than physiological.
  • the lysosomal pH is lower than intracellular or extracellular pH, for example about 4.5, while the aqueous humor of the eye is about 7.5-7.6.
  • pH is a measure of the acidity or basicity of a solution and is written as the negative log of the molar concentration of hydrogen ions in solution.
  • Acidic solutions have a pH less than 7, while basic solutions have a pH above 7.
  • a pH of 7.0 is said to be neutral.
  • Pure water has a pH of about 7.0.
  • pH may be measured electrically or by the use of color changing solutions or compounds. In some cases a colormetric solution may be added dropwise to a test solution, or a test solution may be applied to various papers containing a colormetric compound/solution (test strips). pH may also be assayed electronically by pH meter and comparison to solutions of known pH. pH values may vary +/- 0.1.
  • a pH of 7.6 may include a range from about 7.5 to about 7.7.
  • compositions may include one or more proteins that are modified to be more active in one pH compared to another.
  • the modified protein may be an enzyme with lower activity at physiologic pH compared to non-physiologic pH.
  • the non-physiologic pH may be 2.5-7.0 or 7.5-10.0, for example less than about 7.0, 6.5, 6.0, 5.5, 5.0, 4.5, 4.0, 3.5, or 3.0 and greater than about 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5, or greater than about 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 and less than about 10.5, 10.0, 9.5, 9.0, 8.5, 8.0 and 7.5.
  • the difference in activity at physiologic pH versus non-physiologic pH may be 10%-200%.
  • Protein activity may be measured using various methods. For example, where the protein is an enzyme, the maximal velocity (Vmax molecules/time) may be measured. In these embodiments, the Vmax of the modified enzyme at a non-physiological pH greater than 2%, 5%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%,
  • the difference may be relative to the non-modified protein.
  • the disclosed proteins may have pH profile that varies with pH.
  • the disclosed modified proteins may have a maximal activity at a pH less than about 7 and a minimal activity greater than pH 7.
  • the disclosed modified proteins may have enhanced activity in one or more subcellular or tissue compartments.
  • the modified protein may have enhanced activity, relative to non-modified protein, in the cytoplasm, lysosome, endosome, golgi, secretory vesicle, or mitochondria, and reduced activity, relative to the non-modified protein (or the modified protein at non-physiological pH), at physiological pH.
  • the modified proteins may have low activity in compartments, tissues, and organelles, with physiologic pH and higher activity in compartments, tissues, and organelles, with non-physiologic pH.
  • the modified protein is an enzyme with enhanced catalytic activity at a non-physiologic pH, and/or a greater activity at non- physiologic pH, relative to physiologic pH.
  • the disclosed modified proteins may have enhanced activity at one or more tissues.
  • the disclosed modified proteins may be useful for treating a disease of the
  • the lysosome is a membrane-bound cellular organelle found in nearly all animal cells. Lysosomes generally contain about 60 different enzymes to metabolize biomolecules within the lysosome’s lumen. The lumen, or interior, of the lysosome has an acidic pH in the range of about 4.5 - 6.5, for example 4.5 - 5.0. Most lysosomal enzymes are optimized to catalyze reactions at this acidic pH. The lysosome is typically thought of as a waste disposal system for the cell, and its enzymes help digest unwanted materials found with the in and around the cell. These materials may come from outside of the cell, or may be the cell’s own materials that have become damaged or are no longer needed. Extracellular material found in the lysosome may be taken-up through endocytosis, and intracellular material through autophagy.
  • Lysosomal storage diseases are generally inherited metabolic diseases. In most cases, these diseases and disorders result from the build-up of various materials in a cell’s lysosome. In some cases, these disorders are due to a deficiency in one or more enzymes, or in proteins involved in membrane transport. Due to these deficiencies, large amounts of material may build up in the lysosome, causing it to swell and eventually kill the cell. [0046] Lysosomal storage disorders can affect many different systems and tissues, including the skeleton, skin, heart, and central nervous system. New lysosomal storage disorders continue to be identified.
  • a disease may not be, traditionally, considered as a lysosomal storage diseases, but may function similar to that of a lysosomal storage disease.
  • age-related macular degeneration AMD
  • atherosclerosis is associated with the buildup of cholesterol and 7- keto cholesterol (7KC).
  • lysosomal storage diseases are caused, generally, by insufficient or ineffective enzymes (due to insufficient quantities, missing, mutant, or damaged enzymes), they can, in some cases, be treated by replacing or augmenting the enzyme. In some embodiments, replacement may be accomplished by expressing a recombinant version of the missing or damaged enzyme. This may be referred to as enzyme replacement therapy, or ERT.
  • enzyme replacement therapy or ERT.
  • Macular degeneration is the loss of vision in the center of the visual field. It is typically seen in older people and is the major cause of vision loss and blindness in this population. This type of MD is usually referred to as age-related macular degeneration, or AMD. There are three types of MD: early, intermediate, and late. Late type MD has two forms‘dry’ and‘wet’. The dry form accounts for the majority of macular degeneration cases, and is typically the less serious form, caused by the loss of light-sensing cells
  • RPE cells are essential support cells found in the macula.
  • the RPE cells are important in that they support the light sensitive photoreceptor cells.
  • MD RPE cells experience an accumulation of debris, termed lipofuscin, within the cell’s lysosomes. Enlargement of the lysosomes, due to build-up of lipofuscin, affects the ability of RPE cells to properly support the photoreceptor cells. Eventually the RPE cells may die. Failure and death of RPE cells, in turn leads to death of the photoreceptors and thus a progressive loss of vision. Extracellular accumulations of debris, termed drusen, also increases as MD progresses.
  • Lipofuscin mediated RPE cell death is thought to be a contributing factor to the formation of drusen. As drusen accumulates, it too can destabilize the macular region by contributing to inflammation, complement activation, and other processes. Thus, over time, dry MD progresses to the wet form of macular degeneration, also referred to as neovascular macular degeneration.
  • Lipofuscin comprises the bisretinoid N-retinylidene-N-retinylethanolamine (A2E; Figure 1 top) and its photoisomers, which have adverse effects due to their amphiphillicity and photoreactivity.
  • A2E bisretinoid N-retinylidene-N-retinylethanolamine
  • lysosomal A2E accumulation is also seen in patients with Stargardt disease (SD), and Best vitelliform macular dystrophy.
  • Atherosclerosis is associated with the buildup of cholesterol and its oxidized derivatives (particularly 7-ketocholesterol or 7KC) in the lysosome.
  • One way to treat this disease may be to restore or augment the body’s ability to metabolize cholesterol and/or 7-ketocholesterol.
  • Enzymes are catalytic proteins. In most cases, a specific enzyme is optimized to catalyze reactions in a specific environment. For example, some enzymes are optimized to survive and be active in the stomach (which is very acidic - 1.5-3.5 pH), while other enzymes are optimized for activity at very high or low temperatures (e.g. taq polymerase is active at 75-80 °C). In most cases, an enzyme that is optimized for one environment will not work, or will work poorly (slowly and or indiscriminantly) in a different environment. Thus, an enzyme intended to catalyze a reaction at physiologic pH may function poorly in the stomach or in a lysosome.
  • the disclosed modified enzymes may be optimized to catalyze reactions in an environment that is different than the native, non-modified enzyme’s environment.
  • the modified enzymes are optimized for activity in the lysosome (i.e. less than about 7.0) while being inactive, or less active, at physiologic pH (i.e. 7.0 - 7.5).
  • peroxidases catalyze the oxidation of a molecule using hydrogen peroxide.
  • Various peroxidases are well known in the art. Some peroxidases, for example horse radish peroxidase, and manganese peroxidase are useful in oxidizing aromatic compounds.
  • Aromatic compounds include biomolecules with one or more aromatic carbon ring structure.
  • Manganese peroxidase oxidizes Mnll (Mn 2+ ) to form Mnlll (Mn 3+ ) in the presence of hydrogen peroxide (H2O2). The Mnlll is stabilized by organic acid to form a diffusible complex that attacks a variety of compounds including aromatic compounds.
  • the disclosed manganese peroxidase is obtained from a fungus, for example Pleurotus ostreatus or Phanerochaete crysosporium.
  • the peroxidase genes may be from a mammalian or plant source.
  • the amino acid sequence of the disclosed enzymes may be altered, relative to the native enzyme’s amino acid sequence.
  • the amino acid sequence is altered to help alter the modified enzyme’s glycosylation pattern.
  • one or more asparagine residues in the native sequence may be changed to a different amino acid (for example to a similarly charged amino acid - e.g. glutamine - or a smaller residue, e.g. alanine or glycine; these may be referred to as conservative mutations) to remove one or more glycosylation sites.
  • residues other than asparagine may be changed to asparagine to add a glycosylation site.
  • Other target residues may also be changed to add or remove a glycosylation site.
  • Mutations to or from a glycosylated residue may include non-conservative substitutions or conservative substitutions at those specific positions (conservative/non conservative substitutions may be based on charge, hydrophobicity, size, etc).
  • One such weighting algorithm may be found at homology database server www.clustal.org/clustal2/, among others.
  • Conservative amino acid changes involve substitution of one type of amino acid for the same type of amino acid. For example, where charge is being conserved, changing lysine to arginine is a conservative change, whereas changing lysine to glutamic acid is non-conservative.
  • a change from glutamic acid to glutamine may be conservative, while a change from glutamic acid to glycine may be non conservative.
  • amino acids can be classified based on known behavior and or characteristic chemical, physical, or biological properties based on specified assays or as compared with previously identified amino acids.
  • the gene sequence for the disclosed modified enzymes may be synthesized, in vitro mutagenesis and selection, site-directed mutagenesis, error prone PCR,“gene shuffling” or other means can be employed to obtain random and/or directed changes in the protein sequences of naturally occurring genes coding for disclosed enzymes. These methods permit production of a polypeptide having a modified glycosylation pattern relative to native polypeptides. If desired, specific regions of the disclosed enzymes important for glycan attachment can be identified, and targeted for amino acid changes that would result in modifications to the glycosylation pattern. Mutants may also include deletions, insertions and point mutations, or combinations thereof.
  • enzymes may be identified that destroy the material building up in the lysosome.
  • an exogenous enzyme may be engineered to function in the lysosome and then targeted to the lysosomes of affected cells. This method may be referred to as enzyme augmentation therapy (EAT).
  • EAT enzyme augmentation therapy
  • Targeting one or more enzymes to a cell suffering from lysosomal storage disorder may help to alleviate the disorder.
  • a native lysosomal enzyme may be targeted to the lysosome to compensate for a deficient and/or mutant enzyme.
  • non-lysosomal enzymes may aid in alleviating lysosomal storage disorders.
  • the enzyme may not be optimized to work in the acidic environment of the lysosome.
  • enzymes may be targeted to the lysosome by expressing recombinant modified enzymes with lysosomal targeting tags, or by importing modified enzymes from outside the cell.
  • Some enzymes may be modified for high activity at lysosomal pH, and inactive at physiologic pH. This may help to avoid the enzyme from targeting unintended substrate materials.
  • enzyme optimization may increase the safety, efficacy, and/or stability.
  • modification to the glycosylation state of the enzyme may be useful in tune the stability and activity of the enzyme at one or more pH.
  • nucleic acids of the present invention can be produced by any synthetic or recombinant process such as is well known in the art. Nucleic acids according to the invention can further be altered to provide for the disclosed modified enzymes. In some embodiments, the nucleic acid sequences coding for the disclosed enzymes may be modified by adding one or more sequences that code for a lysosomal targeting sequence. [0062] The disclosed nucleic acid sequences can include one or more portions of nucleotide sequence that are non-coding for the disclosed enzyme. In some embodiments, the nucleic acid sequences may include one or more regions that aid in expression of the gene in a particular host organism.
  • Host cells for expressing the disclosed genes, include various organisms that do or do not support glycosylation including bacterial cells such as E. coli, yeast and fungi such as Pichia pastoris, and mammalian cells such as Chinese hamster ovary (CHO) cells and myeloma cells.
  • bacterial cells such as E. coli, yeast and fungi such as Pichia pastoris
  • mammalian cells such as Chinese hamster ovary (CHO) cells and myeloma cells.
  • the rMnP was engineered to remove the endogenous fungal secretion signal and stop codon, and to include a His tag and a Pichia pastoris secretion tag. Secretion tag exports it into the media, purified by NiNTA.
  • Native rMnP was trimmed using a PNGase F kit purchased from New England Biolabs, Inc (Ipswich, MA) according to the manufacturer’s instructions. Briefly, 30 pL of 17.85 pg/pL rMNP was combined with 53.5 pL of the supplied 10x GlycoBuffer 2, 30 pL of the supplied PNGaseF, and 422 pL of house deionized water. In parallel, 5.6 pL of 17.85 pg/pL rMNP was combined with 10 pL supplied GlycoBuffer2 and 84.4 pL house deionized water as a temperature only control.
  • GlycoBuffer2 2 mI_ supplied 10% NP-40, 5 mI_ house deionized water, and 1 mI_ supplied PNGaseF.
  • a combined 50 mM sodium phosphate/50 mM sodium acetate buffering system containing 150 mM NaCI and 0.2% triton X-100 was prepared as follows: 1.1 g monosodium phosphate, 1 1.2g disodium phosphate, 4.102g sodium acetate, and 8.79 g of NaCI were added to 800 ml_ of deionized water, after mixing the dried material into solution, the volume was brought up to 1 L. 2 M HCI was added continuously in small volumes to reach the following pH conditions: 7.5, 7.0, 6.5, 6.0, 5.5, 5.0, 4.5. At each of the specified pH conditions, 50 ml_ were drawn and placed into 50 ml_ conical tubes. From each tube, 100 mI_ of buffer were removed and 100 mI_ of Triton X-100 were added and mixed by repeated inversion until in solution. Buffer conditions were then retested to confirm pH stability prior to use.
  • each sample was treated with 250 mI of 2:1 dichloromethane: methanol (166 mI_ dichloromethane, 83 mI_ methanol) then vortex mixed and inverted by hand to stop the reaction by denaturing the rMnP.
  • Samples were centrifuged on a tabletop centrifuge for 10 min. Using a pipette equilibrated with dichloromethane, the lower organic phase of each sample containing dichloromethane and A2E was drawn up and placed into new 1.5 ml_ microcentrifuge tubes. The tubes containing the organic phase were then centrifuged in a speed-vac vacuum concentration system at 37 °C under low vacuum for 45 min to remove the solvent from each sample. 400 mI_ of methanol were then added to each sample, which were thoroughly vortexed for 1 min to dissolve the dried residue. Each sample was centrifuged to pellet any insoluble matter that may damage the HPLC system prior to injection.
  • a PerkinElmer LC Flexar HPLC system equipped with a UV/VIS detector and run with Chromera software was used for HPLC analysis (PerkinElmer, Inc. Waltham, Massachusetts, U.S).
  • a reverse phase C18 column (4.6*150mm, 5mM, Cosmosil 5C18-AR- II, Nacalai, Japan) was used for the entire analysis.
  • a mixed solvent system of methanol and water with trifluoroacetic acid (TFA) was used for the mobile phase, run isocratically with a composition of 90% Methanol/10% water with 0.1 % TFA with a flow rate of 1.0 ml/min for a total run time of 10 min.
  • Injection volumes were 10 pL and the column was held at a constant temperature of 26 °C. Detection was performed at 430 nm. Enzyme activity was determined by fitting the linear portion of the A2E concentration vs protein concentration curve and taking the slope. Activity was normalized to the maximum activity observed.
  • FIG. 5 includes a diagram of the digestion pattern for Endo H (upper) on an oligosaccharide; green balls are mannose, purple squares are N-acetylglucosamine (GlcNAc), Asn is asparagine on the protein backbone, and P is phosphate. The site of cleavage is shown as a single red line between the two GlcNAc residues.
  • FIG. 6 includes a diagram of the digestion pattern for B14 (upper) on an oligosaccharide; green balls are mannose, purple squares are N-acetylglucosamine (GlcNAc),‘Asn’ is asparagine on the protein backbone, and‘P’ is phosphate. The site of cleavage is shown as a single red line between the second GlcNAc residue and first mannose.
  • FIG. 7 includes a diagram of the digestion pattern for Endo H (upper) on an oligosaccharide; green balls are mannose, purple squares are N-acetylglucosamine
  • FIG. 8 includes a diagram of the digestion pattern for Endo H (upper) on an oligosaccharide; green balls are mannose, purple squares are N-acetylglucosamine
  • rMNP control contained 300 ul 242 pM rMnP + 80 ul 5x activity buffer + 20 ul water; and glycosidase digestion contained 300 ul 242 mM rMnP P +80 ul 5X activity buffer + 20 ul glycosidase (1 Unit of enzyme).
  • Results are graphed for pH 4.5 to 7.8 at FIG. 9. This showed that, compared to non-modified enzyme, there was reduced activity of A(1-2,3,6) mannosidase cleaved rMnP at pH conditions greater than about 6.8, and similar activity at pH of 4.5 to 6.0.
  • FIG. 10 shows Absorbance vs Time graphs of individual activity studies for the graph shown in FIG. 9. Top graph is undigested rMnP and bottom graph is enzyme treated rMnP.
  • FIG. 11 is shows activity and normalized activity, as above, based on three studies where rate was determined over 40-50 minutes.
  • rMNP control contained 300 ul 242 mM rMnP + 80 ul 5x activity buffer + 20 ul water; and glycosidase digestion contained 300 ul 242 mM rMnP P +80 ul 5X activity buffer + 20 ul glycosidase (40 Units of enzyme).
  • Results are graphed for pH 4.5 to 7.8 at FIG. 12.
  • rMnP treated with A(1-6) showed similar activity relative to non-modified enzyme and modified enzyme across tested pH.
  • FIG. 13 shows three bar graphs with non-modified rMnP (light grey), A(1 -2,3,6) treated rMnP (grey), and A(1-6) treated rMnP (black).
  • the top graph shows normalized reaction velocity at pH 5.1
  • middle graph shows normalized reaction velocity at pH 7.2
  • bottom graph shows normalized reaction velocity at pH 7.5.
  • Example 9 Comparison of Non-Modified rMnP, A(1 -2,3,6) treated rMnP, and A(1-6) treated rMnP
  • FIG. 14 shows all normalized reaction velocities on one graph.
  • Blue line is non- modified rMnP
  • red line is A(1-2,3,6) treated rMnP
  • grey line is A(1-6) treated rMnP.
  • Example 10 - pH Profile of A2E Digestion by rMnP +/- ENDO H
  • rMNP control contained 300 ul 242 mM rMnP + 80 ul 5x activity buffer + 20 ul water; and glycosidase digestion contained 300 ul 242 mM rMnP P +80 ul 5X activity buffer + 20 ul glycosidase (0.1 unit of enzyme).
  • Results are graphed for pH 4.5 to 7.8 at FIGs. 15 and 16 (upper graph is activity vs. pH, and lower graph is normalized reaction velocity). As with A(1-6), Example 7, while the two studies showed variability, they demonstrate similar activity relative to non-modified enzyme and modified enzyme across tested pH.
  • rMNP control contained 300 ul 242 mM rMnP + 80 ul 5x activity buffer + 20 ul water; and glycosidase digestion contained 300 ul 242 mM rMnP P +80 ul 5X activity buffer + 20 ul glycosidase (0.1 Unit of enzyme).
  • Results are graphed for pH 4.5 to 7.8 at FIG. 17 (upper graph is activity vs. pH, and lower graph is normalized reaction velocity). As with A(1-6) and ENDO H, these studies showed similar activity relative to non-modified enzyme and modified enzyme across tested pH.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des enzymes ayant une dépendance au pH ajustable conçues pour une utilisation dans le traitement de maladies, troubles et états divers. Dans certains modes de réalisation, l'enzyme est une peroxydase ayant un motif de glycosylation qui est modifié à partir de celui de l'enzyme native. L'enzyme peut être administrée à un patient présentant un trouble de stockage lysosomal, tel que la dégénérescence maculaire, l'enzyme étant moins active dans des compartiments et des organites ayant un pH physiologique, et étant relativement plus active dans les compartiments et les organites ayant un pH qui est inférieur au pH physiologique.
PCT/US2019/019420 2018-02-26 2019-02-25 Amélioration de thérapies d'augmentation enzymatique par modification de la glycosylation WO2019165369A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862635333P 2018-02-26 2018-02-26
US62/635,333 2018-02-26

Publications (2)

Publication Number Publication Date
WO2019165369A2 true WO2019165369A2 (fr) 2019-08-29
WO2019165369A3 WO2019165369A3 (fr) 2019-10-17

Family

ID=67688497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/019420 WO2019165369A2 (fr) 2018-02-26 2019-02-25 Amélioration de thérapies d'augmentation enzymatique par modification de la glycosylation

Country Status (1)

Country Link
WO (1) WO2019165369A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153310A (en) * 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
WO2009089396A2 (fr) * 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugaison de polypeptides employant des oligosaccharyltransférases
CN102482656A (zh) * 2008-08-29 2012-05-30 埃欧金能源公司 具有提高的稳定性的经修饰的β-糖苷酶

Also Published As

Publication number Publication date
WO2019165369A3 (fr) 2019-10-17

Similar Documents

Publication Publication Date Title
CA2692854C (fr) Polypeptide ace2
CA2767473C (fr) Proteines a forte teneur en mannose et methodes de production desdites proteines
Kallas et al. Enzymatic properties of native and deglycosylated hybrid aspen (Populus tremula× tremuloides) xyloglucan endotransglycosylase 16A expressed in Pichia pastoris
KR102028228B1 (ko) 폼페병의 치료를 위한 방법 및 물질
EP1408117B1 (fr) Glycoprot ine et proc d de production
KR102736071B1 (ko) 재조합 히알루로니다제의 생산 방법
KR20220069045A (ko) 안정성이 향상된 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물
EP2714752A2 (fr) Procédés de couplage de peptides de ciblage sur des enzymes lysosomales recombinantes pour des traitements améliorés de maladies de stockage lysosomal
US20090246187A1 (en) Process for concentration of a polypeptide
EP1472346A2 (fr) Procede pour produire des proteines de recombinaison dans des micro-organismes
JP6594896B2 (ja) 修飾スルファミダーゼ及びその製造
EA022220B1 (ru) Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы
WO2019165369A2 (fr) Amélioration de thérapies d'augmentation enzymatique par modification de la glycosylation
US20180258408A1 (en) Modified lysosomal protein and production thereof
US20250122492A1 (en) N-terminal and/or C-terminal Cleaved Soluble PH20 Polypeptide and Use Thereof
EP2143790B1 (fr) Batroxobine recombinante purifiée à haute activité spécifique
KR20010041235A (ko) 히알루론 산을 소화하는 미생물 효소를 함유하는 약학적제제
TWI803946B (zh) 製造重組玻尿酸酶的方法
Koyuturk Production of recombinant A1AT with human glycosylation profile In CHO cells and its interaction with asialoglycoprotein receptors
EP3871687A1 (fr) Thérapie de remplacement d'enzymes pour le traitement de la maladie de pompe
WO2024040072A2 (fr) Compositions, méthodes et systèmes reposant sur peroxydase dirigée par cellules rétiniennes pigmentaires épithéliales (rpe)
Bonifert Glyco-engineered horseradish peroxidase for targeted cancer treatment
BOND ROBERT J. BEYNON

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19758190

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19758190

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载